Find clinical trials for Chronic Lymphocytic Leukemia in Paris, Île-de-France
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Chronic Lymphocytic Leukemia trials near Paris, Île-de-France, FRA:
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...
Phase 2
Paris cedex 13, France and 73 other locations
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...
Phase 3
Bobigny, France and 130 other locations
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
Paris, France and 212 other locations
levels of Pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic...
Phase 2
Argenteuil, Val-d'Oise, France and 137 other locations
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; par...
Phase 3
Paris, Cedex 13, France and 179 other locations
Epcoritamab will be tested either inRelapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as:* Monotherapy, or* Com...
Phase 1, Phase 2
Paris, France and 86 other locations
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...
Phase 3
Villejuif, France and 86 other locations
rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic...
Phase 3
Paris, France and 153 other locations
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...
Phase 3
Paris CEDEX 14, Paris, France and 63 other locations
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Paris, France and 180 other locations
Clinical trials
Research sites
Resources
Legal